Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Provided By GlobeNewswire
Last update: Mar 25, 2024
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse
